Citicoline (CDP-Choline)
Choline donor and membrane phospholipid precursor
Citicoline shows a modest signal in vascular cognitive impairment and some stroke-recovery contexts, though the largest stroke trial was null. Evidence for cognitive enhancement in healthy adults is weak and short-term, and nothing supports dementia prevention.
How confident is BioSignal?
Our overall position, and how sure we are of it across each dimension — including where we are not sure at all.
Limited evidence
Citicoline shows a modest signal in vascular cognitive impairment and some stroke-recovery contexts, though the largest stroke trial was null. Evidence for cognitive enhancement in healthy adults is weak and short-term, and nothing supports dementia prevention.
Early or sparse human evidence; conclusions remain uncertain.
Biological Role
Citicoline is an endogenous intermediate in phosphatidylcholine synthesis, supplying both choline and cytidine — a genuinely characterised role in membrane biology.
Human Evidence
Multiple randomised trials exist in cognitive impairment and stroke, but results are inconsistent and trial quality is heterogeneous. Studies in healthy adults are small.
Supplement Benefit
Where benefit appears, it is in impaired populations and of modest magnitude. Benefit in healthy people is not established.
Broader Claims
Dementia prevention and general cognitive enhancement are not supported. Investigational uses such as glaucoma neuroprotection remain preliminary.
Safety Confidence
Consistently well tolerated across trials, including at the higher doses used in stroke research.
Research Activity
Long-standing research activity, historically concentrated in Europe and Japan where it is a prescription medicine.
Where the evidence stands today
How mature the science is, what kinds of evidence exist, and — the part nobody else prints — what is still missing.
6/9
steps proven in humans
Evidence-rich
Proven at every applicable step — rare, and worth noticing.
Guideline / regulatory support
LimitedUsed clinically in some countries; not standard elsewhere.
Clinical outcomes
LimitedMixed; no dementia-prevention evidence.
Large human RCTs
LimitedICTUS (stroke) was null.
Small human outcome trials
ProvenCognitive impairment studies.
Human safety data
ProvenWell tolerated in trials.
Human biomarker / pharmacology
ProvenCholine availability; imaging correlates.
Animal
ProvenNeuroprotection models.
Cell / in vitro
ProvenMembrane and neurotransmitter pathways.
Mechanistic plausibility
ProvenCholine donor; membrane phospholipid synthesis.
The bottom line
What we know, what we think, what we don't know — and what would change our mind.
What We Know
Citicoline is a real biochemical intermediate in membrane synthesis, is well tolerated, and has more human trial data behind it than any other popular cognitive supplement.
What We Think
The signal — such as it is — lies in impairment rather than enhancement: vascular cognitive impairment and some post-stroke settings, not healthy adults chasing sharper focus.
What We Don't Know
Whether the benefit in vascular cognitive impairment is real and clinically meaningful. The large ICTUS stroke trial was null, which tempers the earlier positive literature considerably.
Active Research
Continuing investigation in mild cognitive impairment, vascular cognitive impairment, and glaucoma-related neuroprotection.
What Could Change Our Mind
Large, rigorous trials with objective cognitive endpoints in clearly defined populations — the kind of trial that ICTUS was for stroke, but for cognition.
The biggest myth
“Citicoline enhances cognition in healthy adults”
Evidence in healthy people is confined to small, short studies with surrogate endpoints. Enhancement in people without impairment is not established.
Ask BioSignal
Still have a question about citicoline (cdp-choline)?
Answers are retrieved from this record and the rest of the knowledge graph — never generated.
Why people take citicoline (cdp-choline)
Popularity is not evidence — but it is not stupid either. This explains the interest on its own terms.
Citicoline is the supplement most often cited as 'the one nootropic with real evidence.' That's partly fair — it has the most human data — but the data are mixed, concentrated in impaired populations, and do not support enhancement or prevention.
If you're here because…
Jump straight to the part of the evidence that answers your question.
Approval, safety and regulatory
What it is approved for, who should be careful, what remains unknown — and the limits of what this evidence can tell you.
Regulatory status
Not FDA-approved as a drug (supplement in the US; prescription in some countries)
Availability
Supplement (US); prescription elsewhere
Sport (WADA)
Not a prohibited class (confirm at publication)
Known safety profile
Citicoline is generally well tolerated in trials, including at the higher doses used in stroke research. Adverse effects are uncommon and usually mild.
Common issues
- Occasional gastrointestinal upset
- Headache (uncommon)
- Insomnia (uncommon)
Use caution if
- People who are pregnant or breastfeeding (limited data)
- People taking cholinergic medications (theoretical additive effect)
- People with Parkinson's disease taking levodopa (interaction data are limited)
Long-term unknowns
The effects of long-term supplementation in healthy people have not been characterised, since most trials were conducted in impaired populations over months rather than years.
Limits of this evidence
Trials are heterogeneous in population, dose, and endpoint. Much of the positive literature comes from smaller studies and from regions where citicoline is a marketed medicine; the largest and most rigorous trial was null. Good tolerability is not evidence of benefit.
Full regulatory and sport detail
- Regulatory approval
- Not FDA-approved as a drug in the US (sold as a supplement); approved/prescribed in some other countries.
- Approved indication
- Varies by jurisdiction (cognitive impairment/stroke in some).
- Research chemical
- N/A.
- Sport (WADA)
- Not a WADA-prohibited class — confirm against the current list.
- Publication note
- Re-confirm regulatory and anti-doping status against primary sources at publication.
Demand, separated from evidence
Every claim people make about this, counted against what the evidence actually showed.
BioSignal evaluated 8 popular claims about citicoline (cdp-choline).
Here is where each one landed — including the claims of harm, where “not established” is reassuring rather than damning.
- Mixed evidence
- 2
- Insufficient evidence
- 4
- Not established
- 2
Popularity is not evidence. This is simply a count of every claim BioSignal evaluated on this page, sorted by what the evidence actually showed — the full reasoning behind each verdict is in the Evidence Review below.
Mixed evidence
- Citicoline helps vascular cognitive impairment
- Citicoline improves stroke recovery
Insufficient evidence
- Citicoline prevents dementia or Alzheimer's disease
- Citicoline is superior to ordinary choline supplements
- Citicoline protects vision in glaucoma
- Citicoline improves attention in healthy young people
Not established
- Citicoline enhances cognition in healthy adults
- Citicoline is a proven treatment for Alzheimer's disease
The evidence review
Every claim with the reasoning behind its verdict, the doses actually studied, where scientists agree and disagree, and the questions still open.
What people claim
Every popular claim, with BioSignal’s verdict and how confident we are in it. The verdicts are always visible; open any claim to read the evidence behind it.
Citicoline helps vascular cognitive impairmentMixedLimited evidence
Several trials and reviews suggest modest benefit on memory and behaviour in older adults with cerebrovascular-related cognitive impairment. Results are inconsistent and the certainty of evidence is low.
Citicoline improves stroke recoveryMixedModerate confidence
Earlier trials and pooled analyses suggested benefit, but the large ICTUS trial in moderate-to-severe acute ischaemic stroke found no improvement in recovery versus placebo. The most rigorous test was negative.
Citicoline prevents dementia or Alzheimer's diseaseInsufficient evidenceModerate confidence
No adequate trial evidence bears on dementia prevention. No supplement is established to prevent dementia, and citicoline is not an exception.
Citicoline is superior to ordinary choline supplementsInsufficient evidenceLimited evidence
Citicoline delivers choline alongside cytidine and is often argued to be better utilised, but head-to-head outcome trials against other choline sources are lacking.
Citicoline protects vision in glaucomaInsufficient evidenceLimited evidence
Preliminary studies, largely from a small number of research groups, have explored citicoline as a neuroprotective adjunct in glaucoma. This is investigational and not established practice.
Citicoline improves attention in healthy young peopleInsufficient evidenceLimited evidence
A small number of short studies report attention effects in younger populations. The sample sizes and durations do not support a general conclusion.
Citicoline is a proven treatment for Alzheimer's diseaseNot establishedModerate confidence
Citicoline is not an established treatment for Alzheimer's disease and is not recommended as one in major guidelines.
Doses used in human studies
What was actually given to participants in the research. These are descriptions of studies, not recommendations.
Acute ischaemic stroke (trials)
- Intervention
- Oral/IV citicoline
- Dose
- ~2,000 mg/day (as used in ICTUS)
- Duration
- Weeks
- Outcome
- Global recovery after stroke
- Notes
- The largest trial at this dose was null; descriptive of protocol, not a recommendation
Vascular cognitive impairment / MCI (trials)
- Intervention
- Oral citicoline
- Dose
- ~500–1,000 mg/day
- Duration
- Months
- Outcome
- Cognitive and behavioural scores
- Notes
- The setting where any signal is most plausible; results mixed
Healthy adults (studied)
- Intervention
- Oral citicoline
- Dose
- ~250–500 mg/day
- Duration
- Weeks
- Outcome
- Attention and processing-speed measures
- Notes
- Small, short studies; enhancement not established
Glaucoma (investigational)
- Intervention
- Oral citicoline as adjunct
- Dose
- ~500–1,600 mg/day in reported studies
- Duration
- Months
- Outcome
- Visual-field and electrophysiological measures
- Notes
- Preliminary; not established practice
Where scientists agree — and don’t
Agreed
- Citicoline is well tolerated across a wide dose range.
- It is mechanistically plausible as a choline and cytidine donor for membrane synthesis.
- Most of the meaningful data come from impaired populations, not healthy ones.
Debated
- Whether the benefit reported in vascular cognitive impairment is real and clinically meaningful.
- What role, if any, citicoline has after stroke given the null ICTUS result.
- Whether earlier positive trials reflect genuine effect or smaller-study bias.
Unknown
- Any effect in healthy adults on objective cognitive performance.
- Long-term outcomes with continued use.
- The optimal dose and duration, if a meaningful effect exists at all.
What remains unknown
- Is there a real, clinically meaningful benefit in vascular cognitive impairment?
- What explains the discrepancy between earlier positive stroke trials and the null ICTUS result?
- Does citicoline do anything measurable for cognition in people without impairment?
- Is citicoline meaningfully different in effect from other choline sources?
- Does the investigational glaucoma signal survive larger, independent trials?
Questions people actually ask
What is citicoline?
Citicoline (CDP-choline) is a naturally occurring intermediate your body uses to build phosphatidylcholine, a major component of cell membranes. Taken orally, it supplies both choline and cytidine. It is sold as a supplement in the US and prescribed as a medicine in some other countries.
How does citicoline work?
It contributes to the pathway that builds and repairs neuronal membranes, and it supports choline availability for acetylcholine synthesis. That mechanism is real — but a real mechanism does not guarantee a clinical benefit, which is precisely where citicoline's evidence becomes uncertain.
Is citicoline worth taking for brain health?
It is the best-evidenced of the popular cognitive supplements, but that is a low bar. The signal is mainly in vascular cognitive impairment, with mixed results, and a large stroke trial was null. It will not prevent dementia — blood pressure, exercise, sleep, and metabolic health do far more.
What was the ICTUS trial and why does it matter?
ICTUS was a large international randomised trial of citicoline in moderate-to-severe acute ischaemic stroke. It found no benefit over placebo on recovery. It matters because it was the most rigorous test of the most promising indication — and it was negative. Earlier smaller positive studies should be read in that light.
How is citicoline different from Alpha-GPC?
Both are choline-donating compounds marketed for cognition. Citicoline has more and better human trial data, concentrated in impaired populations; Alpha-GPC has less, and carries an unresolved observational signal regarding stroke risk. Neither is established for cognitive enhancement in healthy people.
Practical takeaways
- Citicoline has the most human evidence of the popular cognitive supplements — but that is a low bar, and results are mixed.
- The signal is in impairment (vascular cognitive impairment, stroke), not healthy enhancement.
- The largest stroke trial, ICTUS, was null — a fact often omitted in marketing.
- It is consistently well tolerated, including at high doses.
- It is not established to prevent dementia; the vascular and lifestyle levers matter far more.
How it works
The mechanism comes last on purpose. A compelling explanation of how something might work is the easiest part of the story to tell, and the part most likely to outlive the evidence for it.
Citicoline is an endogenous intermediate in phosphatidylcholine synthesis, supplying both choline and cytidine — a genuinely characterised role in membrane biology.
How we found out
Pharmacological Origins
Citicoline was characterised as an endogenous intermediate in membrane phospholipid synthesis and developed as a medicine for cerebrovascular indications.
European and Japanese Clinical Adoption
Citicoline entered clinical use in several countries for stroke and cognitive impairment, supported by trials that were generally small and positive.
The ICTUS Result
A large international randomised trial in moderate-to-severe acute ischaemic stroke found no benefit over placebo, materially tempering the earlier positive literature.
Current Research
Investigation continues in mild and vascular cognitive impairment and in glaucoma-related neuroprotection, alongside supplement marketing that outpaces the evidence.
References
Verified sources. BioSignal does not print a citation it has not checked.
- 01
Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study
Lancet 380(9839):349-357 · 2012
- 02
Citicoline: pharmacological and clinical review
Rev Neurol (serial updates) · 2016
Version history
Version 1.1
Expanded to the Creatine Signal Record benchmark during the Brain Ecosystem quality review. The ICTUS null result was promoted into the claims, evidence, and question surfaces so it cannot be missed. Evidence calibration unchanged.
Version 1.0
Initial review-hardened record (Emerging; limited confidence). Review cadence: Annually.
Continue exploring
Three places this record leads next.